Press Releases

Date Title and Summary Additional Formats
Toggle Summary Radius Health Announces Scientific Presentations on abaloparatide at ASBMR 2020 Annual Meeting
Includes detailed results from Phase 2 histomorphometry study and Teijin’s Phase 3 trial in Japan WALTHAM, Mass. , Sept. 09, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced data presentations on abaloparatide-SC at the upcoming American
View HTML
Toggle Summary Radius Health: Enrollment Completed for Phase 3 wearABLe trial
Innovative transdermal technology enables delivery of abaloparatide molecule – a peptide - across the skin Trial success followed by regulatory approval would provide a completely unique drug administration option for postmenopausal women with osteoporosis.
View HTML
Toggle Summary Radius Health to Participate in the Citi 15th Annual BioPharma Virtual Conference and Morgan Stanley Virtual 18th Annual Global Healthcare Conference
WALTHAM, Mass. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Radius Health , Inc. (Nasdaq: RDUS) today announced its participation in the following conferences in September 2020. Radius Health management will host virtual meetings with investors during the Citi 15 th  Annual BioPharma Virtual
View HTML
Toggle Summary Radius Health Provides Business Update
TYMLOS ® patent extended to 2031, adding approximately 3½ years to the TYMLOS-SC patent life Enrollment completed for ATOM Phase 3 study assessing the efficacy and safety of abaloparatide-SC in males with osteoporosis WALTHAM, Mass. , Aug. 25, 2020 (GLOBE NEWSWIRE) -- Radius Health , Inc. (“Radius”
View HTML
Toggle Summary Radius Health Announces Second Quarter 2020 Operating Results
TYMLOS ®   U.S. net sales of $50   million, with 22% year over year growth Completion of enrollment in ATOM Phase 3 expected this week Phase 3 Trials: wearABLe and EMERALD remain on track Conference call scheduled for 8:30 a.m. ET today WALTHAM, Mass. , Aug.
View HTML
Toggle Summary Sean Murphy joins Radius Health Board of Directors
WALTHAM, Mass. , Aug. 10, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced the appointment of Sean Murphy to its Board of Directors with immediate effect. Sean has several decades of experience in the industry across pharmaceuticals,
View HTML
Toggle Summary Radius Health to Announce Second Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Monday, August 10, 2020
WALTHAM, Mass. , July 27, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its second quarter financial results on Monday, August 10, 2020 . The Company will host a conference call and live audio webcast at 8:30 a.m.
View HTML
Toggle Summary Menarini Group and Radius Health Announce Global License Agreement for the Development and Commercialization of Elacestrant
Menarini licenses global development and commercialization rights of elacestrant, an oral SERD currently in late stage Phase 3 development Elacestrant further strengthens Menarini’s global oncology portfolio, recently bolstered by the acquisition of Stemline Therapeutics in the U.S.
View HTML
Toggle Summary Pivotal Phase III trial of abaloparatide-SC in Japanese women and men with osteoporosis achieves primary endpoint
Radius partner Teijin Pharma has submitted a New Drug Application  for abaloparatide-SC for treatment of osteoporosis in Japan   WALTHAM, Mass. , May 27, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that its partner, Teijin Pharma Limited
View HTML
Toggle Summary Radius Health Announces First Quarter 2020 Operating Results
TYMLOS® U.S. net sales of $48 million, with 61% year over year growth Our three Phase 3 studies continue to advance amid slowdown in recruitment due to COVID-19 pandemic. Anticipated data read-outs remain on track for second half of 2021 Due to anticipated impact of pandemic, 2020 TYMLOS U.S.
View HTML